DDInter1355 DDInter927
Oxaliplatin is a platinum-based chemotherapy drug in the same family as cisplatin and carboplatin. Compared to cisplatin the two amine groups are replaced by diamino cyclohexane (DACH) group to provide a greater antitumor effect. However, this leads to poorer water solubility, which was compensated by the addition of the chloride moieties. Due to this chemical moiety, oxaliplatin readily undergoes non-enzymatic biotransformation, thus complicating oxaliplatin's pharmacokinetics. Like most platinum-based compounds, oxaliplatin's mechanism of action is primarily through DNA damage through DNA crosslinking, particularly intrastrand and interstrand crosslinking. However, due to the structure of oxaliplatin, its adducts make the binding of mismatch repair protein to DNA harder compared to cisplatin or carboplatin's adducts, resulting in greater cytotoxic effects. The
Inotuzumab ozogamicin is an antibody-drug conjugate using linker and cytotoxic drug technology similar to that developed for the ground-breaking treatment Mylotarg (), which was approved by the US FDA in 2000 for the treatment of acute myeloid leukaemia. Inotuzumab ozogamicin consists of a recombinant humanised IgG4 kappa CD22-targeting monoclonal antibody covalently attached to calicheamicin derivative, N-acetyl-gamma-calicheamicin dimethylhydrazide, which is a potent DNA-binding cytotoxic agent . Developed by Pfizer and UCB, inotuzumab ozogamicin was granted approval by EU in June 2017 followed by FDA on August 17th, 2017 for the treatment of adults with relapsed or refractory B-cell precursor acute lymphoblastic leukemia (ALL). ALL is a rapidly progressing cancer of the bone marrow that is associated with high mortality rates and low therapeutic response from standard chemotherapies in relasping conditions. In a randomized trial, inotuzumab ozogamicin displayed higher percentages of patients undergoing longer periods of complete remission with no evidence of disease in comparison to patients receiving alternative chemotherapy .
Oxaliplatin {u} (Compound) binds {v} (Gene) ATP7B
Oxaliplatin {u} (Compound) is included by {v} (Pharmacologic Class) Platinum-containing Compounds
Oxaliplatin {u} may cause a minor interaction that can limit clinical effects when taken with {v} Sulfamethoxazole
Oxaliplatin {u} may cause a moderate interaction that could exacerbate diseases when taken with {v} Oxaprozin
Oxaliplatin {u} may cause a moderate interaction that could exacerbate diseases when taken with {v} Floxuridine
Oxaliplatin {u} may lead to a major life threatening interaction when taken with {v} Escitalopram
Oxaliplatin {u} may lead to a major life threatening interaction when taken with {v} Dofetilide
Oxaliplatin (Compound) binds ATP7B (Gene)
Oxaliplatin (Compound) is included by Platinum-containing Compounds (Pharmacologic Class)
Oxaliplatin may cause a minor interaction that can limit clinical effects when taken with Sulfamethoxazole
Oxaliplatin may cause a moderate interaction that could exacerbate diseases when taken with Oxaprozin
Oxaliplatin may cause a moderate interaction that could exacerbate diseases when taken with Floxuridine
Oxaliplatin may lead to a major life threatening interaction when taken with Escitalopram
Oxaliplatin may lead to a major life threatening interaction when taken with Dofetilide